Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) have risen more than 2,000% over the past 20 years. Despite a terrific run-up, it’s hard to find an investment bank analyst on Wall Street who expects the stock to fall in the year ahead.
There are 28 analysts following Vertex Pharmaceuticals. None have issued sell ratings, and 15 are calling the stock a buy. A consensus price target of $496.05 implies a gain of about 26% from its closing price on Sep. 12, 2025.
Image source: Getty Images.